Neonatal Outcome After Hexoprenaline Compared with Atosiban After Preterm Premature Rupture of Membranes
Tóm tắt
Preterm premature rupture of membranes (PPROM) occurs in up to 3% of all pregnancies. Only few comparative studies have investigated potential risks and benefits between different tocolytic substances in women with PPROM. The aim of this study was to compare the neonatal short term outcome after tocolysis with Atosiban or Hexoprenaline in women with PPROM. This is a retrospective observational cohort study of women with PPROM between 24 and 32 weeks of gestation comparing neonatal and maternal outcome after tocolysis with atosiban or hexoprenaline. Outcome parameters were short term neonatal outcome, maternal tocolytic efficacy, effectiveness and tolerability and neonatal neurodevelopmental long-term outcome. Continuous variables were compared using t-Test or Mann–Whitney U test, as appropriate. For categorical variables Chi-square after Pearson and Fisher exact-test were used to compare the two groups. 93 women were included into this study with 42 women receiving hexoprenaline and 51 women receiving atosiban as primary tocolytic treatment. Mean gestational age was 29 weeks in both groups at the time PPROM. No differences were found for any short term neonatal outcome parameters, tocolytic efficacy, effectiveness and tolerability and neonatal neurodevelopmental long-term outcome. Both hexoprenaline and atosiban do not affect the short and long term neonatal outcome in women with PPROM for the time of lung maturation.
Tài liệu tham khảo
Parry S, Strauss JF 3rd. Premature rupture of the fetal membranes. N Engl J Med. 1998;338:663–70.
Rubens CE, Sadovsky Y, Muglia L, et al. Prevention of preterm birth: Harnessing science to address the global epidemic. Sci Transl Med. 2014;6:262sr265.
Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol. 2003;101:178–93.
Mackeen AD, Seibel-Seamon J, Muhammad J, et al. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev. 2014;2:Cd007062.
de Heus R, Mol BW, Erwich JJ, et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ. 2009;338:b744.
Doret M, Kayem G. Tocolysis for preterm labor without premature preterm rupture of membranes. J Gynecol Obstet Biol Reprod (Paris). 2016;45:1374–98.
Jorgensen JS, Weile LK, Lamont RF. Preterm labor: current tocolytic options for the treatment of preterm labor. Expert Opin Pharmacother. 2014;15:585–8.
Laohapojanart N, Soorapan S, Wacharaprechanont T, et al. Safety and efficacy of oral nifedipine versus terbutaline injection in preterm labor. J Med Assoc Thail. 2007;90:2461–9.
Papatsonis DN, Flenady V, Liley H. Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour. Cochrane Database Syst Rev. 2013;10:CD005938.
Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006. https://doi.org/10.1002/14651858.CD004454.pub2:Cd004454.
Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1–7.
de Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound. Behav Brain Res. 1992;49:1–6.
Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92:529–34.
Rubaltelli FF, Bonafe L, Tangucci M, et al. Epidemiology of neonatal acute respiratory disorders. A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of Neonatal Pneumology. Biol Neonate. 1998;74:7–15.
Cooke RW. Factors associated with periventricular haemorrhage in very low birthweight infants. Arch Dis Child. 1981;56:425–31.
Kemper AR, Prosser LA, Wade KC, et al. A comparison of strategies for retinopathy of prematurity detection. Pediatrics. 2016. https://doi.org/10.1542/peds.2015-2256
Bayley N. Bayley scales of infant development: New York. New York: The Psychological Corporation; 1969.
Weiner CP, Renk K, Klugman M. The therapeutic efficacy and cost-effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes. Am J Obstet Gynecol. 1988;159:216–22.
Brownfoot FC, Crowther CA, Middleton P. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2008. https://doi.org/10.1002/14651858.CD006764.pub2:Cd006764.
Moutquin JM, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol. 2000;182:1191–9.
[Anonymous]. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. BJOG 2001; 108:133–42.
Azria E, Kayem G, Langer B, et al. Neonatal mortality and long-term outcome of infants born between 27 and 32 weeks of gestational age in breech presentation: the EPIPAGE cohort study. PLoS ONE. 2016;11:e0145768.
Costeloe KL, Hennessy EM, Haider S, et al. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ. 2012;345:e7976.
Wolfensberger A, Zimmermann R, von Mandach U. Neonatal mortality and morbidity after aggressive long-term tocolysis for preterm premature rupture of the membranes. Fetal Diagn Ther. 2006;21:366–73.